Elanco Animal Health Stock Price, News & Analysis

The FDA has approved Zorbium, a new transdermal solution for managing postoperative pain in cats, marking a significant expansion of Elanco's pain management portfolio. This long-acting medication offers up to four days of postoperative pain control from a single dose, reducing the burden on pet owners for at-home medication administration. Anticipated to launch mid-year 2022, Zorbium underscores Elanco's commitment to innovation in veterinary pain relief, addressing an unmet market need.

Elanco Animal Health (NYSE: ELAN) will participate in the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022. CEO Jeff Simmons is set to present at 10:30 a.m. ET, addressing questions from analysts. A live audio webcast of the event will be accessible on Elanco's investor website, with a replay available for 30 days afterward. Elanco is dedicated to improving animal health with nearly 70 years of experience, focusing on creating value for farmers and pet owners through innovative products and services.

Elanco Animal Health (NYSE: ELAN) announced a significant restructuring plan aimed at simplifying its organization, including eliminating approximately 380 positions, or 20% of senior management, which will incur a fourth quarter charge of $65-$71 million. The company expects this restructuring to generate around $70 million in annual savings, directing resources into high-growth areas, especially in digital capabilities and the Chinese market. Despite the restructuring costs, Elanco maintains its goal of achieving a 60% adjusted gross margin by 2023.

Elanco Animal Health (NYSE: ELAN) will participate in the Evercore ISI 4th Annual HealthCONx Conference on Tuesday, November 30, 2021. Jeff Simmons, CEO, will join a virtual fireside chat at 1:50 p.m. ET. A live audio webcast will be available on Elanco’s investor website, with a replay available for 90 days.

Elanco Animal Health (NYSE: ELAN) has joined the Greener Cattle Initiative, committing approximately $5 million over five years to fund research aimed at reducing methane emissions in beef and dairy production. This effort, led by the Foundation for Food & Agriculture Research, responds to the urgent need for climate action as highlighted by the UN. Elanco's participation aligns with its sustainability goals, including its pledge to remove 21 million tons of emissions from customer farms by 2030.

Elanco Animal Health reported a 27% increase in third quarter revenue, reaching $1,131 million, boosted by the Bayer Animal Health acquisition. The company updated its full-year revenue guidance to $4,730 to $4,770 million while maintaining adjusted EPS guidance of $0.97 to $1.03. However, reported EPS was $(0.21). Gross margin improved significantly to 55.6%. Elanco's operational performance reflected strong fundamentals, particularly in the Farm Animal and Pet Health sectors, with significant product contributions. The company anticipates continued growth in 2022.

Elanco Animal Health (NYSE: ELAN) has been recognized in FORTUNE’s 2021 Change the World list, ranking 19th among 53 companies making a social or environmental impact. This accolade highlights Elanco's East Africa Growth Accelerator (EAGA), which supports smallholder farmers in Tanzania, Kenya, and Uganda by providing affordable veterinary products and training. The initiative, begun in 2017 with backing from the Bill & Melinda Gates Foundation, integrates into Elanco's operations, emphasizing animal health's role in addressing hunger and climate challenges.

Elanco Animal Health (NYSE: ELAN) is set to announce its third quarter 2021 financial results on November 5, 2021. A conference call will follow at 8:00 a.m. eastern time to discuss the company's performance, accessible via a live webcast on Elanco's website. The company specializes in products and services aimed at preventing and treating diseases in farm animals and pets, emphasizing sustainability and community impact. With nearly 70 years of experience in animal health, Elanco aims to improve the welfare of animals globally.

Elanco Animal Health (NYSE: ELAN) announces the appointment of Ellen de Brabander, Ph.D., as the new executive vice president of Innovation and Regulatory Affairs, effective October 18. She brings extensive experience, including leading the development of NexGard. The company maintains its innovation revenue expectations of $600 to $700 million by 2025, driven by the acquisition of KindredBio and ongoing pipeline advancements. Additionally, Aaron Schacht will lead the carve-out of Elanco's microbiome R&D platform to establish an independent biopharmaceutical entity.